{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:05:16Z","timestamp":1789877116393,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.jns.2013.11.011","type":"journal-article","created":{"date-parts":[[2013,11,16]],"date-time":"2013-11-16T15:45:50Z","timestamp":1384616750000},"page":"18-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Long-term effects of dalfampridine in patients with multiple sclerosis"],"prefix":"10.1016","volume":"337","author":[{"given":"T.","family":"Ruck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.J.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"G\u00f6bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Wiendl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.G.","family":"Meuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2013.11.011_bb0005","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMra052130","article-title":"Multiple sclerosis \u2014 the plaque and its pathogenesis","volume":"354","author":"Frohman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jns.2013.11.011_bb0010","series-title":"Bradley's neurology in clinical practice","first-page":"92","author":"Daroff","year":"2012"},{"key":"10.1016\/j.jns.2013.11.011_bb0015","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1177\/1352458508088916","article-title":"Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable","volume":"14","author":"Heesen","year":"2008","journal-title":"Mult Scler"},{"issue":"25 Suppl.","key":"10.1016\/j.jns.2013.11.011_bb0020","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1097\/01.wco.0000413319.87092.19","article-title":"Treatment of relapsing\u2013remitting multiple sclerosis: current approaches and unmet needs","author":"Miller","year":"2012","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.jns.2013.11.011_bb0025","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1185\/03007995.2011.583229","article-title":"Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis","volume":"27","author":"Dunn","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jns.2013.11.011_bb0030","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/283570a0","article-title":"Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres","volume":"283","author":"Sherratt","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.jns.2013.11.011_bb0035","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0306-4522(96)00477-0","article-title":"Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord","volume":"77","author":"Shi","year":"1997","journal-title":"Neuroscience"},{"key":"10.1016\/j.jns.2013.11.011_bb0040","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/mus.880030202","article-title":"Facilitatory effects of 4-aminopyridine on normal neuromuscular transmission","volume":"3","author":"Kim","year":"1980","journal-title":"Muscle Nerve"},{"issue":"Pt 1","key":"10.1016\/j.jns.2013.11.011_bb0045","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/brain\/123.1.171","article-title":"Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension","volume":"123","author":"Smith","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.jns.2013.11.011_bb0050","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(09)60442-6","article-title":"Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial","volume":"373","author":"Goodman","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2013.11.011_bb0055","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/ana.22240","article-title":"A phase 3 trial of extended release oral dalfampridine in multiple sclerosis","volume":"68","author":"Goodman","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jns.2013.11.011_bb0060","author":"NHS Commisioning Board"},{"key":"10.1016\/j.jns.2013.11.011_bb0065","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria\u201d","volume":"58","author":"Polman","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jns.2013.11.011_bb0070","series-title":"Multiple Sclerosis Functional Composite (MSFC): administration and scoring manual","author":"Fischer","year":"2001"},{"key":"10.1016\/j.jns.2013.11.011_bb0075","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1177\/1352458509348519","article-title":"The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue","volume":"15","author":"Penner","year":"2009","journal-title":"Mult Scler"},{"key":"10.1016\/j.jns.2013.11.011_bb0080","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1191\/135248506ms1244oa","article-title":"Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis","volume":"12","author":"Kallmann","year":"2006","journal-title":"Mult Scler"},{"key":"10.1016\/j.jns.2013.11.011_bb0085","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/BF00810346","article-title":"Motor responses evoked by magnetic brain stimulation in psychogenic limb weakness: diagnostic value and limitations","volume":"239","author":"Meyer","year":"1992","journal-title":"J Neurol"},{"key":"10.1016\/j.jns.2013.11.011_bb0090","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/1352458510386998","article-title":"Natalizumab restores evoked potential abnormalities in patients with relapsing\u2013remitting multiple sclerosis","volume":"17","author":"Meuth","year":"2011","journal-title":"Mult Scler"},{"key":"10.1016\/j.jns.2013.11.011_bb0095","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2013.11.011_bb0100","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jns.2006.06.031","article-title":"Clinical outcome measures in multiple sclerosis","volume":"259","author":"Amato","year":"2007","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jns.2013.11.011_bb0105","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1212\/WNL.45.11.1956","article-title":"Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo","volume":"45","author":"Krupp","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2013.11.011_bb0110","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1191\/135245801701567050","article-title":"Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine","volume":"7","author":"Rossini","year":"2001","journal-title":"Mult Scler"},{"key":"10.1016\/j.jns.2013.11.011_bb0115","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1212\/WNL.44.9.1701","article-title":"The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study","volume":"44","author":"Smits","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2013.11.011_bb0120","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.expneurol.2013.05.016","article-title":"4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis","volume":"248C","author":"Gobel","year":"2013","journal-title":"Exp Neurol"},{"key":"10.1016\/j.jns.2013.11.011_bb0125","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s004150170222","article-title":"Physiopathology and treatment of fatigue in multiple sclerosis","volume":"248","author":"Comi","year":"2001","journal-title":"J Neurol"},{"key":"10.1016\/j.jns.2013.11.011_bb0130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1017\/S0317167100048691","article-title":"The impact of fatigue on patients with multiple sclerosis","volume":"21","author":"Fisk","year":"1994","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.jns.2013.11.011_bb0135","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.acn.2005.07.006","article-title":"A comprehensive review of the Paced Auditory Serial Addition Test (PASAT)","volume":"21","author":"Tombaugh","year":"2006","journal-title":"Arch Clin Neuropsychol"},{"key":"10.1016\/j.jns.2013.11.011_bb0140","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.pharmthera.2005.10.006","article-title":"Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment","volume":"111","author":"Judge","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jns.2013.11.011_bb0145","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0006-8993(96)00667-1","article-title":"Changes in pharmacological sensitivity of the spinal cord to potassium channel blockers following acute spinal cord injury","volume":"736","author":"Fehlings","year":"1996","journal-title":"Brain Res"},{"key":"10.1016\/j.jns.2013.11.011_bb0150","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.0953-816X.2004.03164.x","article-title":"Temporal and spatial patterns of Kv1.1 and Kv1.2 protein and gene expression in spinal cord white matter after acute and chronic spinal cord injury in rats: implications for axonal pathophysiology after neurotrauma","volume":"19","author":"Karimi-Abdolrezaee","year":"2004","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.jns.2013.11.011_bb0155","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1006\/exnr.1997.6706","article-title":"Conduction block in acute and chronic spinal cord injury: different dose\u2013response characteristics for reversal by 4-aminopyridine","volume":"148","author":"Shi","year":"1997","journal-title":"Exp Neurol"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X13030402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X13030402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T15:59:17Z","timestamp":1688659157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X13030402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":31,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0022510X13030402"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2013.11.011","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term effects of dalfampridine in patients with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2013.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}